Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL12542739 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL4020414 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL16685075 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11039957 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL22721 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL23062790 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL15054707 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20607531 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20535729 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3164373 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110482890-B | Modified citric acid semi-hydrated gypsum and preparation method and application thereof | 江苏一夫科技股份有限公司 | 2020-12-01 | — | — | CN | claimed |
| US-20190282475-A1 | High-Performance Hair Treatment Agents With A Proteolipid And A Magnesium Salt | HENKEL AG & CO. KGAA (DE) | 2019-09-19 | — | — | US | claimed |
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | HENKEL AG & CO. KGAA (DE) | 2017-03-02 | — | — | US | claimed |
| CN-103945865-A | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | RAMSCOR INC | 2014-07-23 | — | — | CN | claimed |
| EP-0066987-B1 | N-(ARYLOXYALKYL)-N'-(AMINO-ALKYL) UREAS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-08-27 | — | — | EP | claimed |
| EP-0066987-A2 | N-(aryloxyalkyl)-N'-(amino-alkyl) ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-15 | — | — | EP | claimed |
| US-20250368630-A1 | PREPARATION OF SUFENTANIL CITRATE AND SUFENTANIL BASE | GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT | 2025-12-04 | — | — | US | disclosed |
| US-12371423-B2 | Preparation of sufentanil citrate and sufentanil base | SpecGx LLC (US) | 2025-07-29 | — | — | US | disclosed |
| US-12295921-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12245995-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2025-03-11 | — | — | US | disclosed |
| US-12150921-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4338804-A2 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230364036-A1 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC | 2023-11-16 | — | — | US | disclosed |
| WO-1998023636-A1 | HEPTAPEPTIDE OXYTOCIN ANALOGUES | FERRING B.V. (NL) | 1998-06-04 | — | — | WO | disclosed |
| US-5064656-A | Swelling disintegrant of starch or crosslinked polyvinylpyrrolidone and effervescant | DR. GERGELY & CO. (CH) | 1991-11-12 | — | — | US | disclosed |
| EP-0066987-B1 | N-(ARYLOXYALKYL)-N'-(AMINO-ALKYL) UREAS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4558155-A | N-(Aryloxyalkyl)-N'-(aminoalkyl)thioureas | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| US-4500529-A | ANTIARRHYTHMIA AGENT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0066987-A2 | N-(aryloxyalkyl)-N'-(amino-alkyl) ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-15 | — | — | EP | disclosed |
| US-3932424-A | Bis-basic ethers of carbazole | RICHARDSON-MERRELL INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12245995-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | MEN1 1268/4885ALDH1A1 645/4885HMGCR 728/4885 |
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | SRRM2, PLP2, KRT18 | MEN1 1264/4885ALDH1A1 4855/4885HMGCR 721/4885 |
| US-12150921-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | MEN1 1268/4885ALDH1A1 645/4885HMGCR 728/4885 |
| US-20190282475-A1 | High-Performance Hair Treatment Agents With A Proteolipid And A Magnesium Salt | SRRM2, PLP2, KRT18 | MEN1 1264/4885ALDH1A1 4855/4885HMGCR 721/4885 |
| US-12295921-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | MEN1 1268/4885ALDH1A1 645/4885HMGCR 728/4885 |
| US-20230364036-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRB2, ADRA2A, ADRA2C | MEN1 1268/4885ALDH1A1 645/4885HMGCR 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.